Clinical trials of resveratrol

Ketan R. Patel, Edwina Scott, Victoria A. Brown, Andreas J. Gescher, William P. Steward, Karen Brown

Research output: Contribution to journalArticlepeer-review

422 Scopus citations

Abstract

An expanding body of preclinical evidence suggests resveratrol has the potential to impact a variety of human diseases. To translate encouraging experimental findings into human benefits, information is first needed on the safety, pharmacokinetics, pharmacodynamics, and, ultimately, clinical efficacy of resveratrol. Published clinical trials have largely focused on characterizing the pharmacokinetics and metabolism of resveratrol. Recent studies have also evaluated safety and potential mechanisms of activity following multiple dosing, and have found resveratrol to be safe and reasonably well-tolerated at doses of up to 5 g/day. However, the occurrence of mild to moderate side effects is likely to limit the doses employed in future trials to significantly less than this amount. This review describes the available clinical data, outlines how it supports the continuing development of resveratrol, and suggests what additional information is needed to increase the chances of success in future clinical trials.

Original languageEnglish
Pages (from-to)161-169
Number of pages9
JournalAnnals of the New York Academy of Sciences
Volume1215
Issue number1
DOIs
StatePublished - Jan 2011
Externally publishedYes

Keywords

  • Clinical
  • Colon
  • Pharmacodynamic
  • Pharmacokinetics
  • Resveratrol
  • Safety

Fingerprint

Dive into the research topics of 'Clinical trials of resveratrol'. Together they form a unique fingerprint.

Cite this